Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
PrEP药物对女性生殖器HIV感染及妇女生殖健康的影响
基本信息
- 批准号:10703238
- 负责人:
- 金额:$ 12.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-14 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAIDS preventionAcademiaAdherenceAdverse effectsAffectAgeAnatomyAntibodiesAwardBiologicalBiological AssayBiopsyBloodCD4 Positive T LymphocytesCaliforniaCellsCoculture TechniquesCoitusCommunicable DiseasesComplexDapivirineDataDecidual Cell ReactionsDevelopmentDevelopment PlansEffector CellEndocervixEndometrialEndometriumEnvironmentExocervixFemaleFemale genitaliaFertilityFibroblastsGastrointestinal tract structureGoalsGonadal Steroid HormonesHIVHIV InfectionsHealthHeterosexualsImmuneImmunophenotypingImpairmentIn VitroInfectionInfection preventionInflammationIntegrase InhibitorsInterferonsInvadedKnowledgeLifeMaintenanceMethodsModelingMonitorMucous MembraneMusNatural Killer CellsOrganoidsOvarian hormonePeriodicityPharmaceutical PreparationsPhenotypePhysiologicalPlayPredispositionPregnancyPregnancy ComplicationsProcessProgesteronePublic HealthRegimenReportingReproductive HealthReproductive ImmunologyReproductive ProcessReproductive Tract InfectionsResearchResearch PersonnelResearch ProposalsResourcesReverse Transcriptase InhibitorsRiskRoleSan FranciscoSeminal fluidSignal TransductionSocioeconomic FactorsSpiral Artery of the EndometriumSurfaceSystemTenofovirTestingTrainingUniversitiesUterusViralWomanWomen&aposs Healthagedcareercareer developmentcell typedesignexperimental studyfetalimmune activationin vivoinfection rateinflammatory milieuinhibitorinsightmen who have sex with menmicrobiome compositionmouse modelmultiple omicsnatural Blastocyst Implantationperipheral bloodpermissivenesspre-exposure prophylaxispreventprophylacticreproductivereproductive system disorderreproductive tractsexual HIV transmissionsingle-cell RNA sequencingtissue culturetooltranscriptometransmission processtrophoblastvaginal microbiomevirologyyoung woman
项目摘要
PROJECT SUMMARY
Worldwide, young reproductive age women account for the majority of new HIV infections, which is often
transmitted through heterosexual intercourse. Pre-exposure prophylactic (PrEP) drugs have been highly
effective in preventing HIV transmission in men who have sex with men (MSM). However, PrEP efficacy in
women has been much more variable, which has been attributed to societal reasons, low adherence, and due
to biological and anatomical differences of the female reproductive tract (FRT) relative to the gastrointestinal (GI)
tract. A number of FRT mucosal factors – including FRT fibroblasts, factors in semen, and inflammation – can
increase HIV infection rates. These same factors can also diminish the anti-HIV activity of PrEP drugs. As many
women at risk of HIV are of reproductive age, it is also important to determine the extent to which PrEP may
affect fertility. Indeed, some PrEP drugs have been reported to impair processes essential for pregnancy. PrEP
has also been shown to elicit interferon signaling in mucosal tissues, which could affect the functions of FRT T
and Natural Killer (NK) cells. Of note, T and NK cells are effector cells that play critical roles in both viral defense
and pregnancy. These observations suggest a better understanding of PrEP within the FRT microenvironment,
and of potential adverse effects of PrEP on pregnancy, is needed. I am pursuing the K99 Award in order to gain
further training to meet my long-term career goals: to become an independent investigator conducting research
on infectious diseases and reproductive disorders affecting women. The environment at Gladstone Institutes and
the University of California at San Francisco are exceptional and will provide the essential resources to
successfully complete my career development plan and achieve my career goals. The objective of this research
proposal is to determine how the environment of the FRT can influence PrEP efficacy, and conversely how PrEP
can influence the FRT to affect fertility. My hypothesis is that FRT mucosal factors adversely affect the anti-HIV
activities of PrEP, and that some but not all PrEP regimens can disrupt FRT processes important for pregnancy.
In Aim 1, I will use FRT infection models and CyTOF to determine how the activity of PrEP is affected by the
environment of the FRT mucosa. In Aim 2, I will use ex vivo tissue culture and organoid models, as well as in
vivo mouse models, to determine how PrEP drugs affect pregnancy and processes important for pregnancy
establishment and maintenance. In Aim 3, I will use multi-omics approaches to characterize T and NK cells from
FRT of HIV-seronegative, reproductive-age women who are on or off PrEP, in order to assess to what extent
PrEP alters the phenotypes of these cells. Identifying the mechanisms underlying HIV infection of susceptible
cells in FRT in the context of suboptimal concentrations of PrEP (which is more common in the FRT than in the
GI tract) will be crucial for the development of effective PrEP that young women can safely use without worrying
about potential pregnancy complications. This could dramatically reduce the rate of transmission in reproductive-
age women and have a significant impact on global public health.
项目摘要
全球,年轻的生殖年龄女性占多数新的艾滋病毒感染,这通常是
通过异性交往传播。暴露前预防性(PREP)药物已高度
有效防止与男性发生性关系的男性(MSM)的艾滋病毒传播。但是,准备效率
妇女的变化要多得多,这归因于社会原因,依从性低和应有的
相对于胃肠道(GI),女性生殖道(FRT)的生物学和解剖学差异
道。许多FRT粘膜因子(包括FRT成纤维细胞,精液中的因素和炎症)可以
提高艾滋病毒感染率。这些相同的因素也可以减少PREP药物的抗HIV活性。就像许多
患有艾滋病毒风险的妇女是生殖年龄,确定PREP可能的程度也很重要
影响生育能力。实际上,据报道,一些预备药物会损害怀孕必不可少的过程。准备
还显示出在粘膜组织中引起干扰素信号传导,这可能会影响frt t的功能
和天然杀手(NK)细胞。值得注意的是,T和NK细胞是在两个病毒防御中起关键作用的效应细胞
和怀孕。这些观察结果表明,对FRT微环境中的准备有更好的理解,
并且需要准备对怀孕的潜在不利影响。我正在寻求K99奖,以获取
进一步培训以实现我的长期职业目标:成为一名独立研究者进行研究
关于影响妇女的传染病和生殖疾病。 Gladstone Institutes和
加利福尼亚大学旧金山分校非常出色,将为
成功完成我的职业发展计划并实现我的职业目标。这项研究的目的
建议是确定FRT的环境如何影响准备效率,相反
可以影响FRT影响生育能力。我的假设是,FRT粘膜因子对抗HIV产生不利影响
准备活动,某些但并非所有的准备方案可能会破坏对怀孕重要的FRT过程。
在AIM 1中,我将使用FRT感染模型和细胞来确定PREP的活动如何受到
FRT粘膜的环境。在AIM 2中,我将使用离体组织培养和类器官模型,以及
体内小鼠模型,确定准备药物如何影响怀孕和对怀孕重要的过程
建立和维护。在AIM 3中,我将使用多摩管的方法来表征T和NK细胞的
艾滋病毒 - 副作用,生殖年龄妇女的妇女正在开放或关闭准备,以评估在多大程度上
PREP改变了这些细胞的表型。确定易感的HIV感染的机制
在次优浓度的PREP的情况下,FRT中的细胞(在FRT中比在FRT中更常见
胃肠道)对于年轻女性可以安全使用而不必担心的有效准备的开发至关重要
关于潜在的怀孕并发症。这可能会大大降低生殖 -
妇女年龄,对全球公共卫生有重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ashley F George其他文献
Ashley F George的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ashley F George', 18)}}的其他基金
Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
PrEP药物对女性生殖器HIV感染及妇女生殖健康的影响
- 批准号:
10548694 - 财政年份:2022
- 资助金额:
$ 12.66万 - 项目类别:
相似国自然基金
去医学化综合性艾滋病暴露前预防决策支持系统及优化
- 批准号:72364039
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
新策略下我国艾滋病预防干预措施效果评估动态模型的构建和应用
- 批准号:81803334
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
基于系统动力学的预防艾滋病经家庭内传播研究
- 批准号:71774150
- 批准年份:2017
- 资助金额:48.0 万元
- 项目类别:面上项目
基于社会心理-行为协同效应的男男性行为者预防艾滋病干预措施及策略研究
- 批准号:71603166
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
基于创新扩散理论的广西农村校外青少年预防艾滋病互联网+健康教育干预研究
- 批准号:71663013
- 批准年份:2016
- 资助金额:30.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Training in HIV Implementation Science and Dissemination in Kenya
肯尼亚艾滋病毒实施科学和传播培训
- 批准号:
10688502 - 财政年份:2023
- 资助金额:
$ 12.66万 - 项目类别:
UCLA Rapid, Relevant, Rigorous Implementation Science Hub
加州大学洛杉矶分校快速、相关、严格的实施科学中心
- 批准号:
10818262 - 财政年份:2022
- 资助金额:
$ 12.66万 - 项目类别:
Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
PrEP药物对女性生殖器HIV感染及妇女生殖健康的影响
- 批准号:
10548694 - 财政年份:2022
- 资助金额:
$ 12.66万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
用于预防艾滋病毒的抗逆转录病毒药物的全身缓释递送
- 批准号:
10449318 - 财政年份:2021
- 资助金额:
$ 12.66万 - 项目类别: